Diffuse large B-cell lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:544C83.3
Who is this for?
Show terms as
4FDA treatments83Active trials147Specialists8Treatment centers6Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Diffuse large B-cell lymphoma, often called DLBCL, is the most common type of non-Hodgkin lymphoma — a cancer that starts in white blood cells called B-cells, which are part of your immune system. In DLBCL, these B-cells grow out of control and form tumors that can appear in lymph nodes (the small glands found throughout your body) or in organs like the stomach, brain, or lungs. The disease is called 'diffuse' because the abnormal cells spread throughout the affected tissue rather than forming a tight cluster. DLBCL can cause swollen lumps under the skin, unexplained fevers, drenching night sweats, and significant weight loss. Some people feel very tired or notice a lump in their neck, armpit, or groin. Because it can grow quickly, symptoms may appear and worsen over weeks rather than months. The good news is that DLBCL is often treatable and can sometimes be cured. The standard treatment is a combination chemotherapy regimen called R-CHOP, which includes the targeted drug rituximab. Many patients respond well to treatment, and newer therapies like CAR-T cell therapy are available for cases that come back after initial treatment. Early diagnosis and prompt treatment give the best chance of a good outcome.

Also known as:

Key symptoms:

Painless swollen lymph nodes in the neck, armpit, or groinUnexplained fever lasting more than a few daysDrenching night sweats that soak clothing or beddingUnexplained weight loss of more than 10% of body weightExtreme tiredness or fatigue that does not improve with restFeeling full quickly or abdominal swelling if the lymphoma is in the bellyShortness of breath or chest pain if lymphoma is in the chestHeadaches, confusion, or vision changes if lymphoma affects the brainItchy skinFrequent infections due to a weakened immune system

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Dec 2026Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center — PHASE2

TrialNOT YET RECRUITING
Jun 2026A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

Sheba Medical Center — PHASE1, PHASE2

TrialNOT YET RECRUITING
Apr 2026Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

American University of Beirut Medical Center — PHASE2

TrialNOT YET RECRUITING
Apr 2026Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Abramson Cancer Center at Penn Medicine — PHASE1

TrialNOT YET RECRUITING
Apr 2026Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Sun Yat-sen University — PHASE1, PHASE2

TrialNOT YET RECRUITING
Apr 2026Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

International Extranodal Lymphoma Study Group (IELSG)

TrialNOT YET RECRUITING
Mar 2026A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies

Cancer Institute and Hospital, Chinese Academy of Medical Sciences — NA

TrialNOT YET RECRUITING
Feb 2026ZYNLONTA: New indication approved
FDAcompleted
Jan 2026CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Tianjin Medical University Cancer Institute and Hospital — PHASE2

TrialRECRUITING
Jan 2026ZYNLONTA: New indication approved
FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

4 available

Rituxan

rituximab· Genentech, Inc.■ Boxed Warning

Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens

Rituxan SC

rituximab and recombinant human hyaluronidase· Genentech, Inc.
Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemo

Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens

Zynlonta

loncastuximab tesirine-lpyl· ADC Therapeutics SAOrphan Drug
treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBC

treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma

MONJUVI

tafasitamab-cxix· Incyte CorporationOrphan Drug
MONJUVI� is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL

MONJUVI� is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)

Clinical Trials

20 recruitingView all trials with filters →
Phase 311 trials
Genotype-guided Treatment in DLBCL
Phase 3
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality · Age: 1880 yrs
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3
Actively Recruiting
· Sites: Chengdu, Sichuan · Age: 1899 yrs
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 3
Active
· Sites: La Jolla, California; Redlands, California +142 more · Age: 1899 yrs
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3
Actively Recruiting
· Sites: Beijing; Changchun +18 more · Age: 1899 yrs
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Phase 3
Active
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Mobile, Alabama; Anchorage, Alaska +323 more · Age: 1880 yrs
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Phase 3
Actively Recruiting
PI: Francesco Merli, Dott. (Reggio Emilia - Azienda Unitа Sanitaria Locale-IRC) · Sites: Brescia, BS; Piacenza, PC +47 more · Age: 6599 yrs
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
Phase 3
Active
PI: Bertram Glaß, Prof. (HELIOS Klinik Berlin-Buch, Klinik für Hämatologie ) · Sites: Graz; Leoben +62 more · Age: 1899 yrs
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Phase 3
Active
PI: Weili Zhao, Professor (Shanghai JiaoTong University School of Medicine,Ru) · Sites: Beijing, Beijing Municipality; Shanghai, Shanghai Municipality · Age: 1880 yrs
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Phase 3
Active
PI: Clinical Trial Management (Regeneron Pharmaceuticals) · Sites: Los Angeles, California; Orange, California +147 more · Age: 1899 yrs
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Phase 3
Active
PI: Pfizer CT.gov Call Center (Pfizer) · Sites: Birmingham, Alabama; Sacramento, California +169 more · Age: 1899 yrs
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Phase 3
Actively Recruiting
· Sites: Gilbert, Arizona; Scottsdale, Arizona +37 more · Age: 1899 yrs
Other7 trials
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Enrolling by Invitation
PI: Bingzong LI (Second Affiliated Hospital of Soochow University) · Sites: Suzhou, Jiangsu · Age: 1899 yrs
Frontline of ASCT in High-risk DLBCL
Actively Recruiting
PI: Jin Lu, M.D. (Peking University People's Hospital) · Sites: Beijing, Beijing Municipality · Age: 1870 yrs
AGMT Austrian Lymphoma Registry
Actively Recruiting
PI: Richard Greil, MD (Department of Internal Medicine III, Paracelsus Me) · Sites: Salzburg, Salzburg · Age: 1899 yrs
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Actively Recruiting
· Sites: Liverpool, Merseyside · Age: 1799 yrs
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Actively Recruiting
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Tianjin, Tianjin Municipality; Beijing +10 more · Age: 1899 yrs
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality · Age: 1899 yrs
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
Enrolling by Invitation
PI: Yuankai Shi, Doctor (Chinese Academy of Medical Sciences) · Sites: Beijing · Age: 1880 yrs

Specialists

Showing 25 of 147View all specialists →
JW
Jason Westin
HOUSTON, TX
Specialist
PI on 2 active trials2 Diffuse large B-cell lymphoma publications
FP
Fabrice Jardin, Pr
Specialist
PI on 1 active trial
CP
Christiane Copie, Pr
Specialist
PI on 1 active trial
PM
Paolo Caimi, MD
CLEVELAND, OH
Specialist
PI on 5 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
WW
Wen-Kai Weng
STANFORD, CA
Specialist
PI on 4 active trials15 Diffuse large B-cell lymphoma publications
CP
Claudio G. Brunstein, MD, PhD
MINNEAPOLIS, MN
Specialist
PI on 6 active trials
CS
Craig Sauter
CLEVELAND, OH
Specialist
PI on 1 active trial1 Diffuse large B-cell lymphoma publication
SM
Stefan Hohaus, MD
Specialist
PI on 2 active trials
SP
Seok Jin Kim, MD, PhD
Specialist
PI on 2 active trials
MM
Margaret L. MacMillan, MD
Specialist
PI on 4 active trials
GM
General Manager
Specialist
PI on 14 active trials6 Diffuse large B-cell lymphoma publications
JP
James L. Rubenstein, MD, PhD
Specialist
PI on 2 active trials

Treatment Centers

8 centers
⚗️ Trial Site

University of Wisconsin Carbone Cancer Center

📍 Madison, Wisconsin

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Financial Resources

6 resources
Rituxan(rituximab)Genentech, Inc.
Rituxan SC(rituximab and recombinant human hyaluronidase)Genentech, Inc.
Zynlonta(loncastuximab tesirine-lpyl)ADC Therapeutics SA
MONJUVI(tafasitamab-cxix)Incyte Corporation

POLIVY

Genentech

Diffuse Large B-cell Lymphoma

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

EPKINLY

Genmab

Diffuse Large B-cell Lymphoma

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Diffuse large B-cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Diffuse large B-cell lymphomaForum →

No community posts yet. Be the first to share your experience with Diffuse large B-cell lymphoma.

Start the conversation →

Latest news about Diffuse large B-cell lymphoma

Disease timeline:

New recruiting trial: Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

New recruiting trial: Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

A new clinical trial is recruiting patients for Diffuse large B-cell lymphoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What subtype of DLBCL do I have, and does it affect my treatment plan?,What stage is my lymphoma, and what does that mean for my prognosis?,Is R-CHOP the right treatment for me, or are there clinical trials I should consider?,What are the most important side effects I should watch for during treatment, and when should I call you?,What is the plan if my lymphoma does not respond to the first treatment or comes back?,Should I have my tumor tested for MYC, BCL2, or BCL6 rearrangements, and what would that mean for my care?,Are there support services — such as social work, nutrition counseling, or mental health support — available to me during treatment?

Common questions about Diffuse large B-cell lymphoma

What is Diffuse large B-cell lymphoma?

Diffuse large B-cell lymphoma, often called DLBCL, is the most common type of non-Hodgkin lymphoma — a cancer that starts in white blood cells called B-cells, which are part of your immune system. In DLBCL, these B-cells grow out of control and form tumors that can appear in lymph nodes (the small glands found throughout your body) or in organs like the stomach, brain, or lungs. The disease is called 'diffuse' because the abnormal cells spread throughout the affected tissue rather than forming a tight cluster. DLBCL can cause swollen lumps under the skin, unexplained fevers, drenching night s

How is Diffuse large B-cell lymphoma inherited?

Diffuse large B-cell lymphoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Diffuse large B-cell lymphoma typically begin?

Typical onset of Diffuse large B-cell lymphoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Diffuse large B-cell lymphoma?

Yes — 20 recruiting clinical trials are currently listed for Diffuse large B-cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Diffuse large B-cell lymphoma?

25 specialists and care centers treating Diffuse large B-cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Diffuse large B-cell lymphoma?

5 patient support programs are currently tracked on UniteRare for Diffuse large B-cell lymphoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.